Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
1.570
-0.030 (-1.88%)
Jun 26, 2025, 4:00 PM - Market closed
Artiva Biotherapeutics Analyst Ratings
Total Analysts
8
Consensus Rating
Strong Buy
Price Target
$18.14
Upside
+1,055.41%
Ratings History
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +664.33% | Jun 11, 2025 |
Needham | Needham | Strong Buy Maintains $23 → $18 | Strong Buy | Maintains | $23 → $18 | +1,046.50% | May 15, 2025 |
Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +1,364.97% | Apr 8, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +1,173.89% | Mar 26, 2025 |
Wedbush | Wedbush | Buy Reiterates $18 | Buy | Reiterates | $18 | +1,046.50% | Mar 25, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $23 → $20 | Buy | Maintains | $23 → $20 | +1,173.89% | Mar 25, 2025 |
Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +1,364.97% | Mar 25, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +1,173.89% | Dec 30, 2024 |
Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +1,364.97% | Nov 13, 2024 |
Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +1,364.97% | Aug 30, 2024 |
Needham | Needham | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +1,364.97% | Aug 13, 2024 |
Wedbush | Wedbush | Buy Initiates $18 | Buy | Initiates | $18 | +1,046.50% | Aug 13, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $23 | Buy | Initiates | $23 | +1,364.97% | Aug 13, 2024 |
TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Aug 13, 2024 |
Jefferies | Jefferies | Strong Buy Initiates $21 | Strong Buy | Initiates | $21 | +1,237.58% | Aug 13, 2024 |